Literature DB >> 12845196

The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma.

Arun Chopra1, Kevin M Brown, Brian R Rood, Roger J Packer, Tobey J MacDonald.   

Abstract

Metastasis is the leading cause of treatment failure in medulloblastoma. Understanding the genetic regulation of metastasis may aid in the development of novel treatments. We therefore performed in silico analysis of the mRNA expression of 83 medulloblastomas compiled from two independent microarray studies by focusing on 135 genes most frequently linked to metastasis in other tumors. We then asked whether expression of these genes correlated with metastasis in the medulloblastoma array data sets. We found the platelet-derived growth factor receptor alpha, early growth response protein 1 and insulin-like growth factor 2 genes as well as several genes associated with MYCC and ERBB2 overexpressed by at least 2-fold in metastatic tumors in both array data sets. We conclude that these genes may interact to promote prometastatic signaling in medulloblastoma. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845196     DOI: 10.1159/000071317

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  12 in total

1.  Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.

Authors:  Sachiko Ohshima-Hosoyama; Monika A Davare; Suresh I Prajapati; Jinu Abraham; Sangeet Lal; Laura D Nelon; Aoife Kilcoyne; Francis J Giles; Martha A Hanes; Brian P Rubin; Charles Keller
Journal:  J Pediatr Hematol Oncol       Date:  2012-03       Impact factor: 1.289

2.  ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration.

Authors:  Liangping Yuan; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald
Journal:  Clin Exp Metastasis       Date:  2010-06-06       Impact factor: 5.150

Review 3.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells.

Authors:  Peng Zhang; Hong Li; Mo-Li Wu; Xiao-Yan Chen; Qing-You Kong; Xiao-Wei Wang; Yuan Sun; Shu Wen; Jia Liu
Journal:  J Neurooncol       Date:  2006-05-25       Impact factor: 4.130

5.  Heparanase expression and TrkC/p75NTR ratios in human medulloblastoma.

Authors:  Neeta D Sinnappah-Kang; Robert E Mrak; Daniel B Paulsen; Dario Marchetti
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

Review 6.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

7.  Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.

Authors:  Tea Blom; Annariikka Roselli; Valtteri Häyry; Olli Tynninen; Kirmo Wartiovaara; Miikka Korja; Kristiina Nordfors; Hannu Haapasalo; Nina N Nupponen
Journal:  J Neurooncol       Date:  2009-09-25       Impact factor: 4.130

8.  Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers.

Authors:  Alvin T Kho; Qing Zhao; Zhaohui Cai; Atul J Butte; John Y H Kim; Scott L Pomeroy; David H Rowitch; Isaac S Kohane
Journal:  Genes Dev       Date:  2004-03-15       Impact factor: 11.361

Review 9.  Medulloblastoma: recurrence and metastasis.

Authors:  Donya Aref; Sidney Croul
Journal:  CNS Oncol       Date:  2013-07

10.  Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.

Authors:  Thamara J Abouantoun; Tobey J MacDonald
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.